“Infusion Devices market set to grow to $2.9bn by 2022” says new Visiongain report

16 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres

Infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices, the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat. For example, both the cancer and diabetes markets are on the rise.

The lead analyst of the report commented "With improved regulations, new infusion pump systems hitting the market are safer, more effective, and are becoming increasingly technologically advanced. This has come at a time when a shift between hospital and home care is happening across the world, though particularly in Europe.

The shift in demand from hospitals to home care settings has been particularly advantageous for insulin pumps, patient-controlled analgesia pumps, and ambulatory pumps due to the increased acceptance by patients and focus for the reduction of overall treatment costs associated with longer hospital stays."

Leading companies featured in the report include Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CME Medical UK Ltd., Fresenius SE & Co. KGaA, ICU Medical, Inc., Johnson & Johnson, Moog Inc., Smiths Group plc, Terumo Medical Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Influenza Vaccines Market Report 2020-2030

For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.

30 September 2020

Read

Visiongain Publishes Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030

Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.

28 September 2020

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever